We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

61 hedge funds and large institutions have $326M invested in Astria Therapeutics in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

931% more call options, than puts

Call options by funds: $3.31M | Put options by funds: $321K

440% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 5

360% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 5

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

267% more capital invested

Capital invested by funds: $88.8M → $326M (+$237M)

55.02% more ownership

Funds ownership: 75.49% → 130.51% (+55%)

42% more funds holding

Funds holding: 43 → 61 (+18)

Holders
61
Holders Change
+18
Holders Change %
+41.86%
% of All Funds
0.98%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.06%
New
23
Increased
27
Reduced
5
Closed
5
Calls
$3.31M
Puts
$321K
Net Calls
+$2.99M
Net Calls Change
+$2.86M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$30.7M
2
DTC
Deep Track Capital
Connecticut
+$18.7M
3
FFM
Fairmount Funds Management
Pennsylvania
+$10.2M
4
ACM
Altium Capital Management
New York
+$9.39M
5
PA
Perceptive Advisors
New York
+$9.37M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$2.48M
2
GTC
Ghost Tree Capital
New York
-$516K
3
AG
Artal Group
Luxembourg
-$301K
4
IC
Ikarian Capital
Texas
-$250K
5
AI
ArchPoint Investors
Florida
-$220K
Name Holding Trade Value Shares
Change 		Change in
Stake
EI
26
EAM Investors
California
$1.36M +$942K +91,345 New
Renaissance Technologies
27
Renaissance Technologies
New York
$1.23M +$252K +24,400 +42%
SCM
28
Silverarc Capital Management
Massachusetts
$1.21M +$837K +81,204 New
Two Sigma Advisers
29
Two Sigma Advisers
New York
$1.18M +$816K +79,134 New
PAMP
30
Polar Asset Management Partners
Ontario, Canada
$1.17M +$814K +78,900 New
Ensign Peak Advisors
31
Ensign Peak Advisors
Utah
$968K +$670K +65,000 New
WMSA
32
Weiss Multi-Strategy Advisers
New York
$961K +$666K +64,568 New
Simplex Trading
33
Simplex Trading
Illinois
$778K +$539K +52,310 New
State Street
34
State Street
Massachusetts
$719K +$198K +19,200 +66%
SSA
35
Schonfeld Strategic Advisors
New York
$552K +$383K +37,100 New
BCM
36
Bridgeway Capital Management
Texas
$521K – – –
Northern Trust
37
Northern Trust
Illinois
$394K +$70.6K +6,846 +35%
SB
38
Samsara BioCapital
California
$372K – – –
CSS
39
Cubist Systematic Strategies
Connecticut
$349K +$90.7K +8,796 +60%
Acadian Asset Management
40
Acadian Asset Management
Massachusetts
$348K +$123K +11,968 +104%
Morgan Stanley
41
Morgan Stanley
New York
$295K +$94K +9,120 +85%
JF
42
Jump Financial
Illinois
$272K +$64.9K +6,291 +52%
Connor, Clark & Lunn Investment Management (CC&L)
43
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$263K +$182K +17,644 New
OC
44
Oppenheimer & Co
New York
$238K -$18.6K -1,800 -10%
TI
45
Trexquant Investment
Connecticut
$230K +$160K +15,475 New
Marshall Wace
46
Marshall Wace
United Kingdom
$223K +$154K +14,949 New
6CM
47
683 Capital Management
New York
$219K +$152K +14,718 New
Qube Research & Technologies (QRT)
48
Qube Research & Technologies (QRT)
United Kingdom
$187K +$129K +12,551 New
Bank of America
49
Bank of America
North Carolina
$165K +$31.1K +3,020 +37%
Jane Street
50
Jane Street
New York
$164K -$108K -10,503 -49%
1
2
3

ATXS Hedge Fund Activity: Q4 2022 in Review

61 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2022, worth a combined $326M — up 267% from $88.8M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ATXS positions and 5 closed out — a net gain of 18 holders — while 27 added to existing stakes and 5 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $30.7M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $2.48M sold.

  • 61 institutional investors held Astria Therapeutics (ATXS) as of Q4 2022, up from 43 in Q3 2022.
  • Funds reported $326M of Astria Therapeutics stock for Q4 2022, up 267% quarter-over-quarter.
  • 23 funds opened new Astria Therapeutics positions in Q4 2022 and 5 closed out, a net change of +18 holders.
  • The largest Astria Therapeutics buyer in Q4 2022 was Fidelity Investments, an estimated $30.7M added.
  • The largest Astria Therapeutics seller in Q4 2022 was Alyeska Investment Group, an estimated $2.48M sold.

Based on aggregated 13F filings for Q4 2022.